Why is ELVN up?
Up 10% on Nov 6, and still 4% over its Nov 5 close.
- It reported a diluted loss of $0.36 a share after the close on Nov 5.
Follow ELVN's trial news. Pro members can get an alert when Enliven Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 10% on Nov 6, and still 4% over its Nov 5 close.
| Holding it back | 25.6% more shares than a year ago |
| Latest filing | 10-Q, Nov 5 |
After its last 4 reports it closed +4.2% on average, higher 4 of 4 times.
The company says its cash lasts into 2030 (8-K, Nov 5).
Chief Medical Officer Helen Louise Collins sold 5,000 shares on Nov 17, under a planned sale. 28 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
ELVN is #74 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 74 |
Share count against a year before: ELVN +26%, SLS +87%, EWTX +3.2%, MBX +42%.
Expected to report Tue Mar 2, after the close (in 101 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.36 a share, from $0.32.
ELVN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Strong balance sheet with $884 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +3.1% | +10.4% | +7.9% |
| Aug 5, 2026 | -0.6% | +0.9% | -3.0% |
| May 7, 2026 | +3.1% | +1.1% | +6.9% |
| Mar 3, 2026 | -0.6% | +4.3% | +5.2% |
RSI 50.4, MACD below signal, above both averages. Not scored.
2 insiders sold $52.3M across 7 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ELVN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
ELVN scores 2 today, which Breakaway calls Below Average. It is #74 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 10% on Nov 6, and still 4% over its Nov 5 close. Shares: 25.6% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ELVN scores 2 today, which Breakaway calls Below Average (0 to 5). That is #74 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ELVN's 2.
2 insiders sold $52.3M across 7 filings in the last 6 months. No open-market buys on record. The newest is J. Scott Garland, Director, who sold $607K on Oct 1. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.